{"api_version":"v1","date":"2026-08-29","conference":null,"generated_at":1788076876077,"digest":{"top_line":"PROTEUS high-risk cohort: 5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u, but source gives no design, N, or treatment.","tldr":"Thin day, prostate only. A high-risk benchmark series reports 5-yr BCR-FS 44% / MFS 71% / CSS 92%, biochemical events well ahead of clinical ones, but with no arms, N, or treatment stated the numbers cannot be attributed to surgery, RT, or systemic therapy. Context only, not an RT decision.","sites":[{"disease_site":"prostate","intro":"One unqualified high-risk outcomes series; no modality attribution, so it sets a benchmark rather than moving a local-therapy decision.","studies":[{"name":"PROTEUS","tldr":"5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median follow-up in a high-risk cohort.","details":["📊 5-yr BCR-FS 44%, 5-yr MFS 71%, 5-yr CSS 92%","📊 Median follow-up 60 mo","🔍 Source tweet frames this as a real-world benchmark to contextualize perioperative treatment strategies in a high-risk population","⚠️ Design not stated in source: no phase, N, arms, or comparator reported","⚠️ Treatment received (surgery, RT, systemic) not specified in source, so the outcomes cannot be attributed to a modality","⚠️ Eligibility and risk-group definition not given in source; \"high-risk\" is unqualified","⚠️ The BCR-FS / MFS / CSS gap (44% vs 71% vs 92% at 5 yr) is consistent with biochemical events outrunning clinical ones, but no competing-risk or per-event detail is reported in source","⚠️ #PROTEUS in the source may refer to the trial hashtag rather than the cohort reported; the tweet gives no registration or design linking the numbers to a named trial"],"figures":[],"nct":null,"doi":null,"tweet_ids":[74],"slug":"proteus","verdict":{"soc_implication":"unclear","rationale":"Source gives three 5-yr rates and follow-up only. No design, N, treatment, or comparator, so no SOC read is supportable.","audience":"High-risk prostate cancer; risk definition and treatment not specified in source"},"significance":null,"monday_clinic":null,"primary_endpoint":null,"analysis_sections":[{"label":"Results","body":"At **median follow-up 60 mo**: **5-yr BCR-FS 44%**, **5-yr MFS 71%**, **5-yr CSS 92%**. No per-arm, per-subgroup, or comparator figures reported in source."},{"label":"Limitations","body":"Beyond the missing design, the source names no treatment received, so the 44% biochemical failure rate cannot be read as a benchmark for any specific perioperative strategy. No N, no risk-stratification criteria, and no confidence intervals accompany the three rates."},{"label":"Applies to","body":"Represents a high-risk prostate cancer cohort as characterised in the source. Does not represent any defined stage, grade, or treatment group, since the source states none."}],"interpretation":null,"relevant_specialties":["radonc","medonc","surgonc"],"significance_by_specialty":null,"open_questions":["Which treatment produced these outcomes","Risk-group definition behind the 44% 5-yr BCR-FS","Whether perioperative systemic therapy improves on this benchmark"],"consort":null,"modality":null,"intent":null,"methodology":null,"related_trials":[{"nct":"NCT06627530","brief_title":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE4"],"enrollment_count":144,"primary_completion_date":"2026-03","brief_summary":"A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer. Prospective, randomized, parallel group, open-label with blinded endpoint adjudication multicenter clinical trial.To assess, among patients with unfavorable intermediate to high-risk prostate cancer, whether a neoadjuvant combined treatment with leuprorelin (Leuprorelin) and darolutamide is superior to monotherapy in terms of complete or almost…","conditions":["Prostate Cancer"],"interventions":[{"name":"Darolutamide Oral Tablet","type":"DRUG"},{"name":"leuprorelin","type":"DRUG"}],"eligibility_brief":"Inclusion Criteria:\n\n* Men ≥18 years of age;\n* Histologically confirmed unfavorable intermediate or high/very high risk non metastatic (by conventional imaging) prostate adenocarcinoma intended for surgery without neuroendocrine differentiation or small cell features;\n* Unfavorable…","answers_question":"Whether perioperative systemic therapy improves on this benchmark","relevance_phrase":"randomised neoadj darolutamide ± leuprorelin pre-RP"},{"nct":"NCT07677566","brief_title":"177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial","overall_status":"NOT_YET_RECRUITING","phase":["PHASE4"],"enrollment_count":20,"primary_completion_date":"2027-07","brief_summary":"The goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy. The main questions it aims to answer are:\n\nDoes this combination treatment improve the pathological complete response rate (pCR)? What is the minimal residual disease (MRD) rate in these patients? What are the safety profiles and any adverse effects associated with this…","conditions":["Prostate Cancer","Prostate Cancer Patients"],"interventions":[{"name":"Darolutamide combined with 177Lu-PSMA-617","type":"DRUG"}],"eligibility_brief":"Inclusion Criteria:\n\n1. Patients must be ≥ 18 and ≤75 years of age\n2. All patients must have a histologically or cytologically diagnosis of prostate cancer，without distant metastasis, and suitable for radical prostatectomy\n3. All patients meet at least one of the following criteria： multi-parameter…","answers_question":"Whether perioperative systemic therapy improves on this benchmark","relevance_phrase":"single-arm neoadj Lu-PSMA + darolutamide, pCR pre-RP"}],"related_trials_provenance":{"queries_fired":["perioperative therapy high-risk prostate cancer"],"queries_failed":[],"candidates_returned":17,"fetched_at":"2026-08-30T08:00:34.951Z","rerank_outcome":"picked_N"},"source_ids":[{"type":"tweet","id":74}]}],"open_questions":null}],"meta":{"clusters_total":1,"studies_analyzed":1,"dropped":[],"ocr_available":true}},"bookmarks":[{"id":74,"url":"https://x.com/candaydogdu/status/2093324225276674361","bookmark_date":"2026-08-29","author_handle":"@CanDAydogdu","author_name":"Can Aydogdu","text":"🔹 Median follow-up: 60 mo\n🔹 5-yr BCR-FS: 44%\n🔹 5-yr MFS: 71%\n🔹 5-yr CSS: 92%\nProviding a real-world benchmark to contextualize perioperative treatment strategies in this high-risk population.\n📄 https://t.co/NyszMg9uCA#ProstateCancer #PROTEUS #Urology","html":"

🔹 Median follow-up: 60 mo
🔹 5-yr BCR-FS: 44%
🔹 5-yr MFS: 71%
🔹 5-yr CSS: 92%
Providing a real-world benchmark to contextualize perioperative treatment strategies in this high-risk population.
📄 https://t.co/NyszMg9uCA#ProstateCancer #PROTEUS #Urology

— Can Aydogdu (@CanDAydogdu) August 28, 2026
\n\n","image_urls":[],"image_ocr_texts":[],"note":null,"fetched_via":"oembed","conference_slug":null}]}